Affinity Asset Advisors’s Immunovant IMVT Stock Holding History

Affinity Asset Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-78,000	Closed	-$2.22M	–	91
2024 Q3	$2.22M	Buy	78,000 +23,700	+44%	+$699K	0.3%	64
2024 Q2	$1.43M	Sell	54,300 -90,100	-62%	-$2.56M	0.17%	75
2024 Q1	$4.67M	Buy	+144,400	New	+$5.27M	0.58%	52
2021 Q4	–	Sell	-30,000	Closed	-$261K	–	63
2021 Q3	$261K	Hold	30,000	–	–	0.07%	70
2021 Q2	$317K	Sell	30,000 -40,000	-57%	-$559K	0.11%	66
2021 Q1	$1.12M	Buy	+70,000	New	+$1.85M	0.38%	46

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Affinity Asset Advisors's IMVT Position: Q2 2026 in Review

Affinity Asset Advisors held its Immunovant (IMVT) position steady in Q2 2026 at 100,000 shares worth $3.85M. The position accounts for 0.17% of the portfolio, ranked #87.

Affinity Asset Advisors first reported a position in IMVT in Q4 2020 and has held it in 13 quarters since. The position peaked at $14.5M in Q4 2023. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

Affinity Asset Advisors held 100,000 shares of Immunovant worth $3.85M as of Q2 2026.
Affinity Asset Advisors left its Immunovant share count unchanged in Q2 2026.
Immunovant made up 0.17% of Affinity Asset Advisors's portfolio in Q2 2026, its #87 holding.
Affinity Asset Advisors first reported a position in Immunovant in Q4 2020 and has held it in 13 quarters since.
Affinity Asset Advisors's Immunovant position peaked at $14.5M in Q4 2023.
227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.